Clinical Trials

300 enrolled

Biliary Tract Neoplasms Immunotherapy

NCT04879654 2024-03-05

SNMM

45 enrolled

Dermatologic

Melanoma

NCT04844385 2024-02-09

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

124 enrolled

Esophageal Squamous Cell Carcinoma

NCT04025931 2023-12-29

Chidamide Combined With Toripalimab in Sarcoma

74 enrolled

Sarcoma

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

6 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT05994456 2023-08-16

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

24 enrolled

Stomach Neoplasms

NCT04135690 2023-08-15

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

60 enrolled

Carcinoma, Hepatocellular

NCT04653480 2023-07-17

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

61 enrolled

Colorectal Neoplasms

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

43 enrolled

Dermatologic

Melanoma

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT04172805 2023-04-12

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

70 enrolled

Sarcoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04667793 2023-04-04

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

15 enrolled

Thymic epithelial tumor

NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

60 enrolled

Biliary Tract Neoplasms, Liver Neoplasms

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

44 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04368078 2023-03-29

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

76 enrolled

Carcinoma, Hepatocellular

NCT05763927 2023-03-10

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

44 enrolled

Rectal Neoplasms

NCT05163483 2023-03-06

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05749575 2023-03-01

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

28 enrolled

Breast

Breast Neoplasms

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05350943 2022-10-18

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

70 enrolled

Biliary Tract Adenocarcinoma

NCT05493332 2022-08-18

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

93 enrolled

Carcinoma, Hepatocellular

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05466019 2022-07-20

A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)

PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05448183 2022-07-07

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

45 enrolled

Cholangiocarcinoma

NCT04398056 2022-07-06

Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

22 enrolled

Nasopharyngeal Carcinoma

NCT05420597 2022-06-15

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

61 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

Small Cell Lung Carcinoma

NCT05342506 2022-04-22

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms

NCT04099589 2022-03-29

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

64 enrolled

Genitourinary

Upper Tract Urinary Carcinoma

NCT04119622 2022-03-11

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Stomach Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast

Breast Neoplasms

NCT05240404 2022-02-15

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

116 enrolled

Carcinoma, Hepatocellular

NCT04177797 2022-02-09

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

20 enrolled

Esophageal Squamous Cell Carcinoma

NCT04995120 2022-01-18

INSIGHT

42 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT05055583 2021-09-24

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05030246 2021-09-01

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

72 enrolled

Refractory Metastatic Digestive System Carcinoma

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

40 enrolled

Nasopharyngeal Carcinoma

NCT04973904 2021-07-22

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

35 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04880811 2021-07-13

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT04955886 2021-07-09

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

14 enrolled

Nasopharyngeal Carcinoma

NCT04395612 2021-05-21

CQGOG0101

38 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04884997 2021-05-13

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

90 enrolled

Dermatologic

Melanoma

NCT04523883 2021-04-15

IMPORT

316 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT04563975 2021-03-17

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

54 enrolled